All In Biotech

Drug Trial Radar · NCT05549726

SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension

A Multisectoral Strategy to Address Persistent Drivers of the HIV Epidemic in East Africa: SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 984 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

984

Actual

Start

Jan 2, 2023

Primary completion

Dec 18, 2023

Study completion Jan 30, 2025

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Infectious Diseases Research Collaboration, Uganda; Makerere University; Kenya Medical Research Institute; University of California, Berkeley; National Institute of Allergy and Infectious Diseases (NIAID); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute of Mental Health (NIMH); National Heart, Lung, and Blood Institute (NHLBI); ViiV Healthcare; University of Pittsburgh
First posted
Sep 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 15 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The overall purpose of this SEARCH CAB-LA (Cabotegravir Injectable Suspension) randomized extension study is to determine if adding the option of CAB-LA as a prevention choice using a person-centered dynamic choice HIV (human immunodeficiency virus) prevention model, with option to switch products over time, compared to the standard of care: 1) increases prevention coverage; 2) reduces HIV incident infection; and 3) increases prevention coverage during periods of self-assessed risk of HIV infection, in three settings in rural Uganda and Kenya. In addition, this study will describe implementation of a person-centered model for dynamic choice HIV prevention including CAB-LA, using the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) evaluation framework among persons randomized to the intervention arm.

Conditions

  • HIV

Interventions

  • Cabotegravir Injectable SuspensionDrug

    CAB-LA will be one of the options for the Dynamic Choice Delivery intervention arm. CAB-LA will be a choice for at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Single-dose vial containing 600 mg/3 mL (200 mg/mL) of cabotegravir is a white to light pink, free-flowing, extended-release injectable suspension. CAB-LA administration will occur at health facilities.

  • Dynamic Choice Delivery ModelOther

    The Dynamic Choice Delivery Model includes integrated PrEP (including CAB-LA) and PEP services at outpatient clinics, antenatal clinics, and via VHT workers in community households. The procedures for each trial include PrEP/PEP counseling and services, choice of service location, HIV testing options, option for longer PrEP refills, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, assessment of PrEP/PEP barriers and personalized actions, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services.

  • Standard of CareOther

    The standard of care differs according to country but does not routinely offer PEP or PrEP to clients seeking services, does not offer choice of service location, HIV testing option or access to medical provider mobile phone number.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Biomedical Prevention Covered TimeTime frame: 48 weeks

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • GPRT / SEARCH Office

    Kisumu, Kenya

  • IDRC Southwest Uganda

    Mbarara, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.